My Md Pharmaceuticals
Pharmaceuticals, 1185 Ave of the Americas, Baltimore, Maryland, 10036, United States, 11-50 Employees
Phone Number: 81********
Who is MYMD PHARMACEUTICALS
MyMD is a clinical stage biotech pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms. MYMD-1 is a drug platform based on a c...
Read More
-
Headquarters: 1185 Ave of the Americas, Baltimore, Maryland, 10036, United States
-
Date Founded: 2014
-
Employees: 11-50
-
Revenue: $5 Million to $10 Million
-
Active Tech Stack: See technologies
Industry: Pharmaceuticals
SIC Code: 2834
Does something look wrong? Fix it. | View contact records from MYMD PHARMACEUTICALS
MyMD Pharmaceuticals Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding MyMD Pharmaceuticals
Answer: MyMD Pharmaceuticals's headquarters are located at 1185 Ave of the Americas, Baltimore, Maryland, 10036, United States
Answer: MyMD Pharmaceuticals's phone number is 81********
Answer: MyMD Pharmaceuticals's official website is https://mymd.com
Answer: MyMD Pharmaceuticals's revenue is $5 Million to $10 Million
Answer: MyMD Pharmaceuticals's SIC: 2834
Answer: MyMD Pharmaceuticals has 11-50 employees
Answer: MyMD Pharmaceuticals is in Pharmaceuticals
Answer: MyMD Pharmaceuticals contact info: Phone number: 81******** Website: https://mymd.com
Answer: MyMD is a clinical stage biotech pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms. MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immunometabolic system to control tumor necrosis factor alpha (TNF-) and other pro-inflammatory cytokines. MYMD-1 is being developed to treat autoimmune diseases, including those currently treated with non-selective TNF- blocking drugs, and aging and longevity. Supera-CBD is a drug platform based on a novel (patent pending) synthetic derivative of cannabidiol (CBD) that targets numerous key receptors including CB2 and opioid receptors and inhibits monoamine oxidase. Supera-CBD is being developed to address the rapidly growing CBD market that includes FDA approved drugs and CBD products not currently regulated as a drug.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month